drugset / Trial / NCT00143325

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

NCT00143325

Phase 3 Completed 730 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.

Timeline

Start
2005-01
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg

Indications

No indication recorded.